The FDA is requiring new warnings regarding potential vision loss risks for GLP-1 weight-loss drugs.
The FDA has ordered GLP-1 drugmakers to add warning labels regarding a rare eye condition. This condition, NAION, can cause sudden, painless, and sometimes irreversible vision loss in one eye. A study found the risk of NAION more than doubled after two years of GLP-1 drug treatment.
- NAION is a condition that can cause sudden, painless, and sometimes irreversible vision loss in one eye.
- The Food and Drug Administration will add the risk to the labeling of all GLP-1 drugs.
Outlets: CBS News, Euronews (FR), NBC News, The Hill, The Independent, TimesLIVE
Written by AI from the outlets' reporting and checked automatically; it can contain mistakes. How Daily Brief works · Privacy